MedElevator Войти в исследования
← Поиск публикаций

DOI 10.36660/abc.20250034

Медицинская библиотека · Arquivos brasileiros de cardiologia · 2025

Systematic Review on the Efficacy of Atenolol in Antihypertensive Treatment: Recommendation from the Brazilian Society of Cardiology.

Brandão Andréa Araujo, Rodrigues Cibele Isaac Saad, Nadruz Wilson, Veiga Jardim Paulo Cesar B, Nobre Fernando, Kaiser Sergio Emanuel, Coelho Otavio Rizzi, Colombo Fernanda Marciano Consolim, Luna Leonardo Castro, Braga Andressa, Morais Quenia Dias, Bortolotto Luiz

СтатьяСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Hypertension (HTN) is a global public health issue, with high prevalence and a significant impact on cardiovascular morbidity and mortality. Cardioselective beta-blockers, such as atenolol, are widely used in the treatment of HTN, although their indication as first-line therapy remains controversial.

OBJECTIVE

To evaluate the efficacy and safety of atenolol in the treatment of primary HTN, compared with other first-line classes of antihypertensive drugs.

METHODS

A systematic review was conducted based on a research question structured using the PICO format. Randomized clinical trials comparing atenolol with other antihypertensive agents were included. Searches were performed in three international databases. Methodological quality was assessed using the RoB 2 tool, and the certainty of evidence was rated using the GRADE system. The primary composite outcome was the occurrence of major cardiovascular events. Secondary outcomes included all-cause mortality, acute myocardial infarction, and stroke, each analyzed separately.

RESULTS

Seven clinical trials met the inclusion criteria. Compared with amlodipine and losartan, atenolol was associated with a slightly higher incidence of cardiovascular events, with low and moderate certainty of evidence, respectively. The combination of hydrochlorothiazide and amiloride demonstrated a greater reduction in cardiovascular events compared to atenolol, although with very low certainty of evidence. Blood pressure (BP) reduction was similar across the compared treatments.

CONCLUSIONS

Despite the limitations of available evidence, atenolol showed comparable efficacy in BP reduction, with small differences in cardiovascular outcomes favoring other antihypertensive classes. Its use may be considered among the options for combination therapy in the treatment of primary HTN in adults. Other beta-blockers were not evaluated in this systematic review.

Для цитирования: Brandão Andréa Araujo, Rodrigues Cibele Isaac Saad, Nadruz Wilson, Veiga Jardim Paulo Cesar B, Nobre Fernando, Kaiser Sergio Emanuel, Coelho Otavio Rizzi, Colombo Fernanda Marciano Consolim, Luna Leonardo Castro, Braga Andressa, Morais Quenia Dias, Bortolotto Luiz. Systematic Review on the Efficacy of Atenolol in Antihypertensive Treatment: Recommendation from the Brazilian Society of Cardiology.. Arquivos brasileiros de cardiologia. 2025. DOI: 10.36660/abc.20250034.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.